Biotechnology Contract Manufacturing Market worth $24.8 billion | MarketsandMarkets

CHICAGO, Sept. 13, 2023 /PRNewswire/ -- In the near future, the biotechnology contract manufacturing industry is poised for unprecedented growth and innovation. With a burgeoning demand for personalized medicines, advanced biologics, and cutting-edge therapies, contract manufacturing organizations (CMOs) will play a pivotal role in expediting drug development and production. This industry's landscape will witness the convergence of state-of-the-art bioprocessing technologies, such as continuous manufacturing and gene editing, allowing for more efficient and scalable production of biopharmaceuticals. Furthermore, the rise of sustainable and eco-friendly bioprocessing techniques will align with global environmental concerns. Collaborations between CMOs, biotech startups, and pharmaceutical giants will become increasingly common, fostering a dynamic ecosystem that accelerates the delivery of life-saving therapies to patients worldwide. As regulatory frameworks adapt to accommodate these advancements, the biotechnology contract manufacturing sector is on the cusp of a transformative era, revolutionizing healthcare and shaping the future of medicine.

Biotechnology Contract Manufacturing Market in terms of revenue was estimated to be worth $16.6 billion in 2023 and is poised to reach $24.8 billion by 2028, growing at a CAGR of 8.3% from 2023 to 2028 according to a new report by MarketsandMarkets™. The growth of this market is driven by the rising demand for biologics and biosimilars, increasing outsourcing of biologics manufacturing among biopharmaceutical companies, growing focus on personalized medicine, increasing collaborations between pharmaceutical companies and biologics contract manufacturers, and advancements in manufacturing technologies. Additionally, the rising demand for cell & gene therapies and the expansion of biologics manufacturing capacities by CMOs will provide growth opportunities in the biotechnology contract manufacturing market.

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=163964739

Browse in-depth TOC on "Biotechnology Contract Manufacturing Market"

287 - Tables
48 - Figures
336 - Pages

Biotechnology Contract Manufacturing Market Scope:

 

The monoclonal antibody segment accounted for the largest share by molecule type in the biotechnology contract manufacturing market in 2022.

By molecule type, the biotechnology contract manufacturing market has been further categorized as monoclonal antibodies, cell therapy & gene therapy, antibody-drug conjugates, vaccines, therapeutic peptides & proteins, and other molecule types. The monoclonal antibodies segment held the largest share of the global biotechnology contract manufacturing market in 2022. This can be attributed to the growing demand for targeted therapies in the treatment of chronic diseases, increasing government initiatives for the development of monoclonal antibody drugs, and the growing number of mAb product candidates currently in development.

The mammalian expression segment accounted for the largest share of the biotechnology contract manufacturing market by source in 2022.

Based on the source, the global biotechnology contract manufacturing market has been segmented into mammalian expressions and non-mammalian expressions. The mammalian expression segment held the largest market share in 2022. The large share of this segment can be attributed to the high sensitivity of this system, its wide usage in the manufacturing of biopharmaceuticals, the growing number of approved biologics based on mammalian expression systems, and the expansion of mammalian-based cell culture capacity by CMOs.

North America region accounted for the dominant share of the biotechnology contract manufacturing market in 2022.

The biotechnology contract manufacturing market in North America has experienced significant growth in recent years. The strong pharmaceutical and biotech industry, the presence of a well-established pharmaceutical industry, the rising demand for biosimilars and biologics, and the increasing outsourcing of manufacturing services by pharmaceutical & biopharmaceutical companies contribute to the growth of the biotechnology contract manufacturing market in the North American region. Additionally, the presence of highly advanced manufacturing technologies makes this region an attractive market for contract manufacturing organizations (CMOs).

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=163964739

Biotechnology Contract Manufacturing Market Dynamics:

Drivers:

1. Rising demand for biologics and biosimilars
2. Increasing outsourcing of biologics manufacturing among biopharmaceutical companies
3. Growing focus on personalized medicine
4. Increasing collaborations between pharmaceutical companies and biologics CMOs
5. Advancements in manufacturing technologies

Restraints:

1. Intellectual property rights issues

Opportunities:

1. Rising demand for cell and gene therapies
2. Significant growth opportunities offered by emerging countries
3. Expansion of biologics manufacturing capacities by CMOs
4. Strong emphasis on drug development

Challenge:

1.  Complying with regulatory reforms

Key Market Players:

Key players in the biotechnology contract manufacturing market include Lonza (Switzerland), Thermo Fisher Scientific Inc. (US), Catalent, Inc. (US), Samsung Biologics (South Korea), WuXi Biologics (China), Boehringer Ingelheim International GmbH (Germany), FUJIFILM Holdings Corporation (Japan), AbbVie, Inc. (US), Eurofins Scientific (Luxembourg), GenScript Biotech Corporation (US), AGC Inc. (Japan), Merck KGaA (Germany), JSR Corporation (Japan) and among others.

Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=163964739

Biotechnology Contract Manufacturing Market Advantages:

• Cost Efficiency: Biotech companies can reduce capital expenses by outsourcing manufacturing processes to specialized contract manufacturing organizations (CMOs), avoiding the need for large-scale infrastructure and equipment investments.
• Expertise and Specialization: CMOs often possess specialized knowledge and expertise in bioprocessing techniques, ensuring high-quality and compliant production, which can be challenging for smaller biotech firms to achieve on their own.
• Scalability: CMOs have the capacity to scale production quickly in response to changing market demands, allowing biotech companies to adapt to fluctuating production requirements without significant lead times or investment.
• Faster Time to Market: Outsourcing manufacturing to CMOs can significantly accelerate drug development timelines, enabling biotech companies to bring their products to market more swiftly and gain a competitive edge.
• Risk Mitigation: Biotech firms can reduce risks associated with manufacturing, regulatory compliance, and quality control by partnering with experienced CMOs, who navigate regulatory hurdles and quality standards on their behalf.
• Focus on Core Competencies: By delegating manufacturing responsibilities, biotech companies can concentrate their resources and efforts on research, development, and innovation, enhancing their ability to bring novel therapies and products to market.
• Global Reach: CMOs often have a global presence, enabling biotech companies to access diverse markets and benefit from regional expertise and regulatory knowledge.
• Cost Transparency: Contract manufacturing agreements often provide cost transparency, allowing biotech firms to plan their budgets more effectively and avoid unexpected expenses.
• Regulatory Compliance: CMOs stay up-to-date with evolving regulatory requirements and quality standards, reducing the regulatory burden on biotech companies and ensuring compliance throughout the manufacturing process.
• Flexibility and Customization: CMOs can tailor their services to meet the specific needs of biotech clients, providing customized solutions for a wide range of biopharmaceutical products.

In summary, the biotechnology contract manufacturing market offers a range of advantages that empower biotech companies to optimize their operations, accelerate product development, and navigate the complexities of drug manufacturing and regulatory compliance more effectively. This strategic partnership model has become instrumental in advancing the biotech industry and improving patient access to innovative therapies.

Recent Developments:

• In January 2023, WuXi Biologics entered into a licensing agreement with GSK plc for using WuXi Biologics' proprietary technology platforms. Under this, GSK was granted an exclusive global license for the research, development, manufacturing, and commercialization of bispecific antibodies in the WuXi Biologics plan.
• In October 2022, Samsung Biologics partnered with GSK plc for the manufacturing of GSK's monoclonal antibody and products, including lupus treatments like Benlysta.

Related Reports:

Clinical Trials Market - Global Forecasts to 2028

Precision Medicine Market - Global Forecasts to 2028

Multimodal Imaging Market - Global Forecasts to 2028

Clinical Trial Imaging Market - Global Forecasts to 2028

Contrast Enhanced Ultrasound Market - Global Forecasts to 2028

About MarketsandMarkets™:

MarketsandMarkets™ has been recognized as one of America's best management consulting firms by Forbes, as per their recent report.

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.

Earlier this year, we made a formal transformation into one of America's best management consulting firms as per a survey conducted by Forbes.

The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines - TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the 'GIVE Growth' principle, we work with several Forbes Global 2000 B2B companies - helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.

To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter, LinkedIn and Facebook.

Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Research Insight: https://www.marketsandmarkets.com/ResearchInsight/biotechnology-ccontract-manufacturing-market.asp
Visit Our Website: https://www.marketsandmarkets.com/
Content Source: https://www.marketsandmarkets.com/PressReleases/biotechnology-ccontract-manufacturing.asp

Logo: https://mma.prnewswire.com/media/660509/MarketsandMarkets_Logo.jpg

 

View original content:https://www.prnewswire.co.uk/news-releases/biotechnology-contract-manufacturing-market-worth-24-8-billion--marketsandmarkets-301925951.html